CG Oncology
CGON | NASDAQ
$84.78
+$10.38 (+13.95%)
At close: Nov 16, 2026, 4:00 PM ET
$83.89
-$0.89 (-1.04%)
After-hours:
Nov 16, 2026, 7:48 PM ET
CG Oncology Company Profile
Company profile explainedCompany Profile
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Key Executives
| Name | Position |
|---|---|
| Arthur Kuan | President, Chairman & CEO |
| James DeTore | Chief Financial Officer |
| Amy Steele | Vice President of Finance & Administration |
| Bing Kung | Vice President of Corporate Development |
| Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary |
| Sarah Connors | Vice President of Communications & Patient Advocacy |
| Swapnil Bhargava | Chief Technical Officer |
| Vijay Kasturi | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | 4 | Filing |
| Oct 19, 2026 | 4 | Filing |
| Oct 19, 2026 | 3 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
CG Oncology
| Country | United States |
| IPO Date | Jan 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Arthur Kuan |
Contact Details
3000 Pegasus Park Drive Dallas,
Texas 75247 United States
Stock Details
| Ticker Symbol | CGON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001991792 |
| CUSIP Number | 156944100 |
| ISIN Number | US1569441009 |
| SIC Code | 2836 |
Recent News
- 14 hours ago / benzinga.comCG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
- 14 hours ago / schaeffersresearch.com2 Cancer-Drug Developers Seeing Unusual Options Volume
- 16 hours ago / investors.comCG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
- 19 hours ago / globenewswire.comPIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
- 11 days ago / zacks.comCG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates
- 11 days ago / globenewswire.comCG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
- 21 days ago / seekingalpha.comCG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy
- 1 month ago / globenewswire.comCG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
- 1 month ago / gurufocus.comKuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
- 2 months ago / seekingalpha.comCG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Add to Watchlist
Select watchlists to add or remove CGON